Galectin Therapeutics Inc (NASDAQ:GALT) investors are overwhelmingly excited today after the drug maker announced its plans to identify a strategic partnership for its galectin-3 …
Galectin Therapeutics Inc (NASDAQ:GALT) shareholders are having a rough day after the biopharmaceutical company announced disappointing topline results from NASH-FX, its Phase 2a clinical …
Galectin Therapeutics Inc (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the appointment of Adam …
